nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

01.06.2015

Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review

verfasst von: V. L. M. Yip, A. Alfirevic, M. Pirmohamed

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2-3/2015

Einloggen, um Zugang zu erhalten

Abstract

Adverse drug reactions (ADRs) are common and are a major problem in drug therapy. Patients experience unnecessary morbidity and mortality whilst many effective drugs are withdrawn because of ADRs in a minority of patients. Recent studies have demonstrated significant associations between human leukocyte antigens (HLA) and predisposition to ADRs such as drug-induced skin injury (DISI) and drug-induced liver injury (DILI). HLA-B*58:01 has been significantly associated with allopurinol-induced hypersensitivity. Associations between HLA and carbamazepine hypersensitivity reactions demonstrate both ethnicity and phenotype specificity; with HLA-B*15:02 associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in South East Asian patients only whilst HLA-A*31:01 is associated with all phenotypes of hypersensitivity in multiple ethnicities. Studies of ximelagatran, an oral direct thrombin inhibitor withdrawn because of hepatotoxicity, found associations between HLA-DRB1*07:01 and HLA-DQA1*02:01 and ximelagatran DILI. Interestingly, HLA-B*57:01 is associated with both abacavir DISI and flucloxacillin DILI but the reasons for the different phenotype of ADR remains unknown. Pharmacogenetic screening for HLA-B*57:01 prior to abacavir therapy has significantly reduced the incidence of abacavir hypersensitivity syndrome in clinical practice. No other HLA associations have been translated into clinical practice because of multiple reasons including failure to replicate, inadequate sample sizes, and our lack of understanding of pathophysiology of ADRs. Here, we review genetic associations that have been reported with ADRs and discuss the challenges that scientists, clinicians, pharmaceutical industry and regulatory agencies face when attempting to translate these associations into clinically valid and cost-effective tests to reduce the burden of ADRs in future.

Aronson JK, Ferner RE (2005) Clarification of terminology in drug safety. Drug Saf 28(10):851–870PubMed

Pirmohamed M, James S, Meakin S et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ: Br Med J 7456:15–19

Davies EC, Mottram DR, Green CF, Taylor S, Williamson PR, Pirmohamed M (2009) Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 4(2):e4439PubMedCentralPubMed

Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA J Am Med Assoc 279(15):1200–1205

FDA Centre for Drug Evaluation and Research (2005) Report to the Nation 2005: Improving Public Health through Drugs. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078935.pdf. Accessed 14 Jan 2013

Rawlins M, Thompson J (1991) Mechanisms of adverse drug reactions. In Textbook of Adverse Drug Reactions. Oxford University Press, Oxford

Pirmohamed M (2012) Genetics and the potential for predictive tests in adverse drug reactions. Chem Immunol Allergy 97:18–31PubMed

Mallal S, Nolan D, Witt C et al (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308):727–732PubMed

Chung W-H, Hung S-I, Hong H-S et al (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982):486–486PubMed

10.

McCormack M, Alfirevic A, Bourgeois S et al (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364(12):1134–1143PubMedCentralPubMed

11.

Hautekeete ML, Horsmans Y, Van Waeyenberge C et al (1999) HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117(5):1181–1186PubMed

12.

Becquemont L (2010) HLA: a pharmacogenomics success story. Pharmacogenomics 11(3):277–281PubMed

13.

Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D (2011) The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 89(6):784–785PubMed

14.

Pirmohamed M, Friedmann PS, Molokhia M et al (2011) Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther 89(6):896–901PubMed

15.

Aithal GP, Watkins PB, Andrade RJ et al (2011) Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89(6):806–815PubMed

16.

Pirmohamed M, Park BK (2001) Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 22(6):298–305PubMed

17.

Alfirevic A, Pirmohamed M (2010) Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. Pharmacogenomics 11(4):497–499PubMed

18.

Roujeau J-C, Kelly JP, Naldi L et al (1995) Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333(24):1600–1608PubMed

19.

Hetherington S, Hughes AR, Mosteller M et al (2002) Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312):1121–1122PubMed

20.

Hughes D, Vilar F, Ward C, Alfirevic A, Park BK, Pirmohamed M (2004) Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14:335–342PubMed

21.

Mallal S, Phillips E, Nolan D et al (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358(6):568–579PubMed

22.

Saag M, Balu R, Phillips E et al (2008) High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 46(7):1111–1118PubMed

23.

Man CBL, Kwan P, Baum L et al (2007) Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5):1015–1018PubMed

24.

Wu XT, Hu FY, An DM et al (2010) Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav 19(3):405–408PubMed

25.

Wang Q, Zhou J-Q, Zhou L-M et al (2011) Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 20(6):446–448PubMed

26.

Hung S-I, Chung W-H, Jee S-H et al (2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 16(4):297–306PubMed

27.

Tassaneeyakul W, Tiamkao S, Jantararoungtong T et al (2010) Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51(5):926–930PubMed

28.

Locharernkul C, Loplumlert J, Limotai C et al (2008) Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49(12):2087–2091PubMed

29.

Then SM, Rani ZZM, Raymond AA, Ratnaningrum S, Jamal R (2011) Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 29(3):290–293PubMed

30.

Mehta TY, Prajapati LM, Mittal B et al (2009) Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 75(6):579–582PubMed

31.

Ozeki T, Mushiroda T, Yowang A et al (2011) Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20(5):1034–1041PubMed

32.

Kim S-H, Lee KW, Song W-J et al (2011) Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 97(1–2):190–197PubMed

33.

Hung S-I, Chung W-H, Liou L-B et al (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102(11):4134–4139PubMedCentralPubMed

34.

Tassaneeyakul W, Jantararoungtong T, Vannaprasaht S et al (2009) Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 19(9):704–709PubMed

35.

Kaniwa N, Saito Y, Aihara M et al (2008) HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9(11):1617–1622PubMed

36.

Ding WY, Lee CK, Choon SE et al (2010) Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 49(7):834PubMed

37.

Kazeem GR, Cox C, Aponte J et al (2009) High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 19(9):661PubMed

38.

Martin AM, Nolan D, James I et al (2005) Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 0101 and abrogated by low CD4 T-cell counts. AIDS 19(1):97PubMed

39.

Vitezica ZG, Milpied B, Lonjou C et al (2008) HLA-DRB1 01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 22(4):540PubMed

40.

Littera R, Carcassi C, Masala A et al (2006) HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20(12):1621PubMed

41.

Gatanaga H, Yazaki H, Tanuma J et al (2007) HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21(2):264PubMed

42.

Chantarangsu S, Mushiroda T, Mahasirimongkol S et al (2009) HLA-B 3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 19(2):139PubMed

43.

Umapathy S, Pawar A, Bajpai S, Pazare AR, Ghosh K (2011) HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients. J Pharmacol Pharmacother 2(2):114–115PubMedCentralPubMed

44.

Likanonsakul S, Rattanatham T, Feangvad S et al (2009) HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther 6:22PubMedCentralPubMed

45.

Gao S, Gui X-E, Liang K et al (2012) HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. AIDS Res Hum Retrovir 28(6):540PubMed

46.

Lonjou C, Borot N, Ledger N et al (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18(2):99–107PubMed

47.

Roujeau J-C, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duédari N (1986) HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens 28(4):251–254PubMed

48.

Romano A, Fonso MD, Venuti A et al (1998) Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann Allergy Asthma Immunol 80(5):433–437PubMed

49.

Özkaya-Bayazit E, Akar U (2001) Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol 45(5):712–717PubMed

50.

Hetherington S, McGuirk S, Powell G et al (2001) Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23(10):1603–1614PubMed

51.

Phillips EJ, Sullivan JR, Knowles SR, Shear NH (2002) Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16(16):2223–2225PubMed

52.

Symonds W, Cutrell A, Edwards M et al (2002) Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 24(4):565–573PubMed

53.

Peyrieère H et al (2001) Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother 35(10):1291PubMed

54.

Nolan D, Martin A, Almeida C, Mallal S (2006) Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 43(1):99–102PubMed

55.

Waters LJ, Mandalia S, Gazzard B, Nelson M (2007) Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 21(18):2533–2534PubMed

56.

Zucman D, Majerholc C, Truchis PD, Stegman S, Caillat-Zucman S (2007) Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 45(1):1–3PubMed

57.

Colombo S, Rotger M, Martinez R et al (2008) The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 198(6):864–867PubMed

58.

Dello Russo C, Lisi L, Lofaro A et al (2011) Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. Pharmacogenomics 12(4):567–576PubMed

59.

Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG (2010) Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. PharmacoEconomics 28(11):1025–1039PubMed

60.

Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE (2008) The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22(15):2025–2033PubMedCentralPubMed

61.

Marson AG, Al-Kharusi AM, Alwaidh M et al (2007) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369(9566):1000–1015PubMedCentralPubMed

62.

Post RM, Ketter TA, Uhde T, Ballenger JC (2007) Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 21(1):47–71PubMed

63.

Cruccu G, Gronseth G, Alksne J et al (2008) AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol Off J Eur Fed Neurol Soc 15(10):1013–1028

64.

Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ (2007) Generation and characterization of antigen-specific CD4+, CD8+, and CD4 + CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 119(4):973–981PubMed

65.

Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M (2006) HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7(6):813–818PubMed

66.

Lonjou C, Thomas L, Borot N et al (2006) A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 6(4):265–268PubMed

67.

Kano Y, Hirahara K, Asano Y, Shiohara T (2008) HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. Acta Derm Venereol 88(6):616–618PubMed

68.

Lim KS, Tan CT, Kwan P (2008) Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurol Asia 13:15–21

69.

Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A (2012) HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 92(6):757–765PubMed

70.

Chen P, Lin J-J, Lu C-S et al (2011) Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364(12):1126–1133PubMed

71.

Locharernkul C, Shotelersuk V, Hirankarn N (2010) HLA-B* 1502 screening: time to clinical practice. Epilepsia 51(5):936–938PubMed

72.

Ferrell PB, McLeod HL (2008) Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9(10):1543–1546PubMedCentralPubMed

73.

Kang HR, Kim YS, Jung JW et al (2011) Positive and negative associations of HLA class i alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 21(5):303–307PubMed

74.

Ostapowicz G, Fontana RJ, Schiødt FV et al (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137(12):947–954PubMed

75.

Sgro C, Clinard F, Ouazir K et al (2002) Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36(2):451–455PubMed

76.

Björnsson E, Jerlstad P, Olsson R, Bergqvist A (2005) Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 40(9):1095–1101PubMed

77.

Temple R (2006) Hepatotoxicity through the years. www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm122149.pdf. Accessed 23 Jan 2013

78.

Russmann S, Kullak-Ublick GA, Grattagliano I (2009) Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 16(23):3041–3053PubMedCentralPubMed

79.

O’Donohue J, Mills PR, Oien KA et al (2000) Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47(5):717–720PubMedCentralPubMed

80.

Donaldson PT, Daly AK, Henderson J et al (2010) Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 53(6):1049–1053PubMed

81.

Lucena MI, Andrade RJ, Stephens C et al (2011) Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class i and II alleles. Gastroenterology 141(1):338–347PubMedCentralPubMed

82.

Daly AK, Donaldson PT, Bhatnagar P et al (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41(7):816–819PubMed

83.

Kindmark A, Jawaid A, Harbron CG et al (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 8(3):186–195PubMed

84.

Singer JB, Lewitzky S, Leroy E et al (2010) A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42(8):711–714PubMed

85.

Yuan J, Guo S, Huang Z et al (2011) Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 25(10):1271–1280PubMedCentralPubMed

86.

Spraggs CF, Budde LR, Briley LP et al (2011) HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29(6):667–673PubMed

87.

Hirata K, Yamamoto M, Okutani Y et al (2008) Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study. Pharmacogenomics J 8(1):29–33PubMed

88.

Ariyoshi N, Iga Y, Hirata K et al (2010) Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab Pharmacokinet 25(3):298PubMed

89.

Andrade RJ, García-Ruiz E, García-Muñoz B et al (2005) Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129(2):512–521PubMed

90.

Chalasani N, Fontana RJ, Bonkovsky HL et al (2008) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135(6):1924–1934, e1924PubMedCentralPubMed

91.

García Rodríguez LA, Stricker BH, Zimmerman HJ (1996) Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 156(12):1327–1332PubMed

92.

Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM (2005) Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 50(10):1785–1790PubMed

93.

Andrade RJ, Lucena MI, Alonso A et al (2004) HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology (Baltimore, Md) 39(6):1603–1612

94.

Russmann S, Kaye JA, Jick SS, Jick H (2005) Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 60(1):76–82PubMedCentralPubMed

95.

Alfirevic A, Pirmohamed M (2012) Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther 92(3):376–380PubMed

96.

Testa L, Bhindi R, Van Gaal WJ, Agostoni P, Abbate A, Biondi Zoccai GGL (2007) The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf 6(4):397–406PubMed

97.

Bonierbale E, Valadon P, Pons C et al (1999) Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid & minus; protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds. Chem Res Toxicol 12(3):286PubMed

98.

Aithal GP, Rawlins MD, Day CP (1999) Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ (Clin Res Ed) 319(7224):1541

99.

Rockey DC, Seeff LB, Rochon J et al (2010) Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 51(6):2117–2126PubMedCentralPubMed

100.

Chessman D, Kostenko L, Lethborg T et al (2008) Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28(6):822PubMed

101.

Alfirevic A, Gonzalez-Galarza F, Bell C et al (2012) In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med 4(6):51PubMedCentralPubMed

102.

Evans WE (2004) Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 26(2):186–191PubMed

103.

Lindh JD, Holm L, Andersson ML et al (2009) Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Eur J Clin Pharmacol 65(4):365PubMed

104.

Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22(8):1382–1388PubMed

105.

Youngster I, Arcavi L, Schechmaster R et al (2010) Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 33(9):713PubMed

106.

Brugts JJ, Isaacs A, Boersma E et al (2010) Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J 31(15):1854PubMed

107.

Veenstra D, Higashi M, Phillips K, Veenstra DL, Higashi MK, Phillips KA (2000) Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2(3):80PubMedCentral

108.

Bodmer W, Bonilla C, Bodmer W et al (2008) Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 40(6):695PubMedCentralPubMed

109.

Szyf M, Szyf M, Szyf M (2007) The dynamic epigenome and its implications in toxicology. Toxicol Sci 100(1):7PubMed

110.

Kacevska M, Ivanov M, Ingelman-Sundberg M (2011) Perspectives on epigenetics and its relevance to adverse drug reactions. Clin Pharmacol Ther 89(6):902–907PubMed

111.

Pirmohamed M (2010) Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin Pharmacol Ther 88(6):862–866PubMed

Titel: Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review
verfasst von: V. L. M. Yip
A. Alfirevic
M. Pirmohamed
Publikationsdatum: 01.06.2015
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2-3/2015
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-014-8418-y

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review

Abstract

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2015

Animal Models of Primary Biliary Cirrhosis

Autoimmune BSEP Disease: Disease Recurrence After Liver Transplantation for Progressive Familial Intrahepatic Cholestasis

Genetics in PBC: What Do the “Risk Genes” Teach Us?

The Coexistence of Sjögren's Syndrome and Primary Biliary Cirrhosis: A Comprehensive Review

Pregnancy and Primary Biliary Cirrhosis: A Case-Control Study

TGR5: Pathogenetic Role and/or Therapeutic Target in Fibrosing Cholangitis?

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

Update HNO